Pharmaceutical sponsor
Beijing InnoCare Pharma Tech Co., Ltd. Clinical Trials
Studies where Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 26Advanced Solid Tumor
Evaluation of ICP-B381 in Patients With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors
- Trial name
- NCT07901413
- Testing
- ICP-B381
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL
- Trial name
- NCT07896590
- Testing
- Orelabrutinib, ICP-248
- Where
- 46 sites in China
- Volunteers
- 292 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Prurigo Nodularis (PN)
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
- Trial name
- NCT07236099
- Testing
- ICP-322
- Where
- 43 sites in United States, China and 3 more
- Volunteers
- 135 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
This study aims to compare the efficacy and safety of ICP-248 in combination with orelabrutinib versus pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma (r/r MCL).
- Trial name
- NCT07784101
- Testing
- ICP-248, Pirtobrutinib, Orelabrutinib
- Where
- 24 sites in China
- Volunteers
- 280 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
- Trial name
- NCT06656494
- Testing
- ICP-248, Azacitidine
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 266 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Primary Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in participants with primary Sjögren's syndrome (pSjS).
- Trial name
- NCT07727486
- Testing
- ICP-488 Tablets
- Where
- 22 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT07082686
- Testing
- ICP-248
- Where
- 29 sites in China
- Volunteers
- 75 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumor
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors
- Trial name
- NCT07617493
- Testing
- ICP-B208
- Where
- China
- Volunteers
- 539 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Health Services Research
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
- Trial name
- NCT07535099
- Testing
- ICP-538 Tablets
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Cutaneous Lupus Erythematosus (CLE)
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in subjects with cutaneous lupus erythematosus (CLE).
- Trial name
- NCT07440537
- Testing
- ICP-488 Tablets
- Where
- 27 sites in China
- Volunteers
- 105 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.